AstraZeneca PLC
AstraZeneca PLC is a global biopharmaceutical company focused on discovering, developing, and commercialising prescription medicines. Its portfolio spans oncology, rare disease, and biopharmaceuticals including cardiovascular, renal & metabolism, and respiratory & immunology, with products sold in more than 125 countries.
Fiscal year 2024 · change from previous year
Development 2019–2024
Business
Share of revenueCancer medicines and related therapeutic products across multiple tumor types.
Treatments for uncommon and often specialized patient populations.
Medicines for cardiovascular, renal & metabolism, and respiratory & immunology.
Customers
AstraZeneca sells primarily to healthcare systems and the institutions that purchase prescription medicines on behalf of patients, including hospitals, clinics, pharmacies, and managed-care or government payers. Its end users are patients with oncology, rare disease, cardiovascular, renal, respiratory, and immunology conditions, but demand is mediated by prescribers and reimbursement systems. The company also interacts with research and clinical-trial ecosystems that support development and adoption of its therapies.
Buy oncology medicines for inpatient, outpatient, and specialty cancer care.
Reimburse medicines and influence access through formulary and coverage decisions.
Dispense rare disease and specialty medicines to patients under prescribed care.
Select AstraZeneca brands for patients in oncology and chronic disease areas.
Use the company’s prescription medicines for treatment of specific diseases.
Strategy
AstraZeneca’s strategy centers on advancing a broad clinical pipeline and turning research into approved medicines across oncology and specialty care. The company also emphasizes global commercialization of its brands, supported by large-scale clinical development and continued expansion into additional indications and markets.
Late-stage assets and new indications drive future branded medicine sales.
Broader market reach improves uptake of approved medicines across countries.
A diversified portfolio reduces reliance on any single therapeutic area.
Geography
AstraZeneca is headquartered in Cambridge, UK, and operates as a global business with medicines sold in more than 125 countries. The company’s commercial exposure is geographically diversified across major healthcare markets in North America, Europe, Asia, and other international markets. Its supply, regulatory, and reimbursement profile is therefore shaped by multiple country-specific approval, pricing, and access regimes.
Risks
AstraZeneca faces the classic biopharma risks of clinical trial failure, regulatory setbacks, patent and lifecycle pressure, and payer-driven pricing constraints. The reports also highlight exposure to intangible asset impairments, legal settlements, and foreign exchange movements, all of which can materially affect reported results in a global medicines business.
- Pricing and reimbursement pressureImpact: HighLikelihood: High
Payers and governments influence access, price realization, and formulary placement.
Exposure: Prescription medicines in major healthcare markets
- Clinical trial and development failureImpact: HighLikelihood: Medium
The business depends on successful late-stage trials to convert research into revenue-generating products.
Exposure: Datroway and broader oncology pipeline
- Regulatory approval delaysImpact: HighLikelihood: Medium
Medicines require approvals in each market before sales can expand.
Exposure: Global product launches and new indications
- Intangible asset impairmentImpact: HighLikelihood: Medium
Acquisition-related and developed product intangibles can be written down if prospects weaken.
Exposure: Acquired assets and capitalized pipeline assets
- Legal settlements and contingenciesImpact: MediumLikelihood: Medium
The company discloses settlement and provision exposure that can materially affect earnings.
Exposure: Litigation and regulatory matters
Accounting
Judgemental itemsAdjusted results exclude amortisation, impairments, legal settlements and restructuring charges.
Impact: Affects comparability of operating performance versus IFRS reported earnings
CER measures remove currency movements, reflecting the multinational revenue base.
Impact: Can materially change growth rates and period-to-period comparability
Acquisition-related and developed product intangibles may require amortisation or write-downs.
Impact: Influences operating profit and earnings volatility
The company carries provisions for legal and other contingent obligations.
Impact: Can create large one-off charges and cash outflows
Similar listed companies
Publicly listed companies with a comparable business focus.
Amgen Inc
AMGN · Biological Products, (No Diagnostic Substances)
Novartis AG
NVS · Pharmaceutical Preparations
Novartis AG is a Switzerland-based medicines company that discovers, develops, manufactures, and commercializes prescription therapies across a broad range of therapeutic areas.
GSK plc
GSK · Pharmaceutical Preparations
GSK plc is a global biopharma company that develops and commercializes prescription medicines, vaccines, and specialty treatments.
Ascelia Pharma
ACE · Health Care
Ascelia Pharma is a Swedish pharmaceutical company headquartered in Malmö, with a US base in New Jersey.
Medtronic plc
MDT · Electromedical & Electrotherapeutic Apparatus
Medtronic plc designs, manufactures, and sells medical technologies used to diagnose, treat, and manage chronic and acute conditions across the body.
Stoke Therapeutics, Inc.
STOK · Pharmaceutical Preparations
Last updated: 28/09/2026